{
    "2020-03-19": [
        [
            {
                "time": "2020-04-20",
                "original_text": "复星医药入局新冠疫苗研发，4月下旬进入临床试验",
                "features": {
                    "keywords": [
                        "复星医药",
                        "新冠疫苗",
                        "临床试验"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-03-19",
                "original_text": "恒指收跌2.61%，卫星无线通讯板块领跌",
                "features": {
                    "keywords": [
                        "恒指",
                        "下跌",
                        "卫星无线通讯"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "金融",
                        "科技"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-03-18",
                "original_text": "辉瑞回应“拒绝向中国提供新冠疫苗”：复星医药已提前拿下中国市场开发和商业权",
                "features": {
                    "keywords": [
                        "辉瑞",
                        "新冠疫苗",
                        "复星医药",
                        "中国市场"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-03-19",
                "original_text": "开盘：恒指小幅低开0.32％ 腾讯业绩增幅超20％涨2.69％",
                "features": {
                    "keywords": [
                        "恒指",
                        "低开",
                        "腾讯",
                        "业绩增长"
                    ],
                    "sentiment_score": 0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融",
                        "科技"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-03-18",
                "original_text": "复星医药控股股东增持712万股 七年研发投入增速34.7%难阻业绩低迷",
                "features": {
                    "keywords": [
                        "复星医药",
                        "控股股东",
                        "增持",
                        "研发投入",
                        "业绩低迷"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}